Kaplan-Meier survival plot of MET-1–bearing NOD/SCID mice. The groups (15 mice/group) included those receiving intravenous PBS, 100 μg HAT, 100 μg MEDI-507 per week for 4 weeks, and a combination of 100 μg MEDI-507 with 100 μg HAT for 4 weeks. Another group received 100 μg MEDI-507 weekly for 6 months. Event-free survival was followed for 180 days. The animals treated in the 4-week HAT, 4-week MEDI-507, 4-week combination of MEDI-507 with HAT, and 6-month MEDI-507 groups had significantly prolonged survivals when compared with the PBS control group (P < .0001). Treatment of tumor-bearing mice with MEDI-507 for 6 months significantly prolonged the survival of the group when compared with the 4-week MEDI-507 treatment group (P < .0036).